Endogenex has filed a notice of an exempt offering of securities to raise $89,555,019.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Endogenex is raising up to $89,555,019.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Stacey Pugh played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Endogenex
Endogenex is a clinical stage company focused on improving outcomes and quality of life for patients living with Type 2 Diabetes (T2D). Endogenex has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with T2D.
To learn more about Endogenex, visit http://www.endogenex.com/
Company Linkedin Page: https://www.linkedin.com/company/endogenexinc/
Contact:
Stacey Pugh, Chief Executive Officer
651-341-3805
https://www.linkedin.com/in/staceypughendogenex/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.